I am biologist with 20 years drug discovery experience across Respiratory and CNS disease areas both within industry and acedmia. Whilst my main remit is to provide in vitro DMPK support for the chemistry programs both here at the MDI and the Sussex Drug Discovery Centre I also provide biochemical/cell based assay development and molecular biology support as required. As of june 2019 I will be embarking on a PhD studying the downstream effects of FMRP1 dysfunction in Fragile-X syndrome.
Howard TD, Whittaker PA, Zaiman AL, Koppelman GH, Xu J, Hanley MT, Meyers DA, Postma DS, Bleeker ER. Identification and association of polymorphisms in the interleukin-13 gene with asthma and atopy in a Dutch population. Am J Respir Cell Mol Biol. 2001 Sep;25(3):377-84.
Trifilieff A, Bench A, Hanley M, Bayley D, Campbell E, Whittaker P. PPAR-alpha and -gamma but not -delta agonists inhibit airway inflammation in a murine model of asthma: in vitro evidence for an NF-kappaB-independent effect. Br J Pharmacol. 2003 May;139(1):163-71.
2013-2018; Research Fellow, Sussex Drug Discovery Centre, Sussex University
After 20 years working in drug Discovery both within industry and academia serving numerous and varied projects I have acquired a broad skill base with which to support MDI activities in a addition to provision of DMPK anayses.
Cloning / Protein expression - DNA/RNA purification, Sanger sequencing, Cloning (Bacterial / Mammalian / Insect expression vectors), Protein expression and purification (Various chromatographic / affinity based methods), Mutant generation, Chromosomal mapping, Real time qPCR (including allelic discrimination).
Biochemical/ cell based assay development - TR-FRET, Fluorescence, Luminescence, FLIPR, ELISA, Transient expression, siRNA inhibition, Transient expression.
Other - Cell culture (primary cells/cell lines), differentiation of primary cell lines to terminal phenotype (HBECs at air/liquid interface).